Search results
Showing 1606 to 1620 of 9098 results
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)
Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Evidence-based recommendations on vamorolone (Agamree) for treating Duchenne muscular dystrophy in people 4 years and over.
Show all sections
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.
Evidence-based recommendations on osimertinib (Tagrisso) for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy in adults.
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over (TA1157)
Evidence-based recommendations on givinostat (Duvyzat) for treating Duchenne muscular dystrophy in people 6 years and over.
Evidence-based recommendations on tisotumab vedotin (Tivdak) for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults.
Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA732
Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.